Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
5.00
+0.14 (2.99%)
Mar 12, 2026, 4:00 PM EDT - Market closed
Molecular Partners AG Revenue
Revenue (ttm)
n/a
Revenue Growth
-29.38%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
153
Market Cap
179.76M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
| Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
| Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
| Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
| Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
| Dec 31, 2019 | 20.38M | 10.03M | 96.84% |
| Dec 31, 2018 | 10.36M | -9.66M | -48.27% |
| Dec 31, 2017 | 20.02M | -3.02M | -13.13% |
| Dec 31, 2016 | 23.04M | -6.08M | -20.88% |
| Dec 31, 2015 | 29.12M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 154.90M |
| Vaxart | 148.20M |
| Zentalis Pharmaceuticals | 26.87M |
| ProQR Therapeutics | 19.19M |
| Caribou Biosciences | 11.16M |
| Whitehawk Therapeutics | 7.15M |
| NeOnc Technologies Holdings | 59.99K |
MOLN News
- 1 hour ago - Molecular Partners Reports Highlights and Financial Results for Full Year 2025 - GlobeNewsWire
- 14 days ago - Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript - Seeking Alpha
- 5 weeks ago - Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 - GlobeNewsWire
- 7 weeks ago - Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 3 months ago - Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting - GlobeNewsWire
- 4 months ago - Molecular Partners AG (MOLN) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program Transcript - Seeking Alpha